

BUSINESS RESPONSE FORM

Nebivolol Tablets 2.5 mg Product Recall – December 6, 2024 Recall # 446

Please fill out this form completely. By doing so, this will acknowledge that you have read and understand the Product Recall instructions and have taken the appropriate action.

Customer Name		DEA#
*DEA # is required, if it is not provided, the	e processing of y	your form will be delayed.
Address		
City	State	Zip
Contact Name (please print)		Telephone #
Contact E-mail :		Fax #
Contact Signature		Date
I have checked my stock and:		
Do not have any stock of recalle	d items.	
OR		
I have quarantined and listed in the box be QUALANEX, as soon as possible. Upon a return authorization label(s) Please indicate	receipt of this R	esponse Form, QUALANEX will issue

Item Description	NDC Number	Lot Number	Sealed Bottle Qty. To Be Returned	Open Bottle Qty. To Be Returned
Nebivolol	59651-137-30	NB0224001A		
Tablets 2.5 mg	59651-137-30	NB0224001B		



Recall # 446

If	you	did	not	purchase	the	product	directly	from	the	Manufacturer,	please	complete	the
<u>be</u>	low :	secti	on.										
Pu	rcha	sed F	rom	: Wholesa	ler N	ame							
Ci	ty									State			
W	holes	saler	DFA	.#									

If you have any questions regarding this form or product return, please contact QUALANEX at 888-504-2014. Office hours 7am to 4pm CST Monday through Friday.

Please fax this form to: 847-737-3719 Or E-mail recall@qualanex.com



December 06, 2024

URGENT DRUG RECALL

Dear Valued Customer,

This is to inform you of a product recall involving:

Product Nebivolol Tablets 2.5 mg

Refer Attachment 1 for NDC, dosage strength, Package Size and Lot details See enclosed product label for ease in identifying the product

Aurobindo Pharma USA, Inc. has initiated a voluntary Drug Product Recall for the product Nebivolol Tablets 2.5 mg from USA market due to presence of Nitrosamine Drug Substance Related Impurity (NDSRI), N-Nitroso Nebivolol above acceptable intake (AI) limit.

Nebivolol Tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. To date, Aurobindo has not received any reports of adverse drug events that are confirmed with this recall. Patients who are prescribed Nebivolol should continue taking their medication, as the risk of harm to the patient's health may be higher if the treatment is stopped immediately without any alternative treatment. Patients should contact their pharmacist or physician who can advise them about an alternative treatment prior to returning their medication.

As per the product information leaflet, Nebivolol Tablets 2.5 mg are light blue colored, round shaped, biconvex uncoated tablets debossed with 'L' on one side and '78' on the other side.

Aurobindo USA began shipping impacted batches to customers nationwide from June 13, 2024 to November 20, 2024.

Please complete and return the enclosed product return response form (business response form) as soon as possible. Consequently, please examine your inventory and quarantine the product batches subject to this recall. In addition, if you have further distributed these batches, please notify your customers accordingly and contact Qualanex with any questions. The product can be identified by checking the product name and batch or lot number on the product label.

As this recall should be carried out to the retail level, your assistance is appreciated and necessary to ensure patient safety.



Recall Instructions:

Please perform the following activities:

- Immediately examine your inventory and quarantine the specified lots of Nebivolol Tablets 2.5 mg.
- Immediately discontinue the distribution of the specific lots being recalled.
- Promptly complete the Product Return Response Form even if you have no product to return. If you have further distributed this product, notify your customers of this recall by including a copy of this notice.
- In the event you have the recall product, please return it to Qualanex, LLC., using the enclosed postage paid product return label and mail to the following.

Qualanex, LLC.

1410 Harris Road

Libertyville, IL 60048

Completed product response form (Yes) may be return by the following methods:

- Email to recall@qualanex.com
- Fax to 847-737-3719
- Mail to:

Aurobindo USA C/O Qualanex LLC 1410 Harris Rd Libertyville, IL 60048

Please complete and return the enclosed Product Return Response Form as soon as possible. If you need assistance in returning your product or have questions about the recall process, contact Qualanex at 888-504-2014 during the hours of 7:00 AM to 4:00 PM CST.

Please return your product along with return goods authorization form using postage paid shipping label included in your recall return packet. Once the response form is received, a return authorization will be generated and e-mailed to you to be included with your recall returns. Appropriate reimbursement for the product returns will be issued on the receipt upon the recall product.

This recall is being made with the knowledge of the Food and Drug Administration.



Sincerely,

Linda Torres


Digitally signed by Linda Torres
District Unda Torres, co-Aurobindo Phare
out-0A Product Compalarix,
email-lineres-Bauerobindo.
Debre 2004-12.06 07:065:26-40:007

Ms. Linda Torres **QA Product Complaint Manager** Aurobindo Pharma USA, Inc 279 Princeton-Hightstown Rd East Windsor, NJ 08520-1401

Direct Email: LTorres@aurobindousa.com

Phone-732-839-9419 Fax-732-289-6189

The product label is as shown below:





Attachment - 1

Batches manufactured at APL Healthcare Limited Unit-IV

NDC Number	Dosage Strength	Package Size	Lot Number	Expiration Date
59651-137-30	2.5 mg	30's HDPE Container	NB0224001A	04/2027
59651-137-30	2.5 mg	30's HDPE Container	NB0224001B	04/2027